Barry R. Davies

Biochemistry, Genetics and Molecular Biology · Life Sciences

43h-index6.9kcitations374works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PI3K/AKT/mTOR signaling in cancer(108), Prostate Cancer Treatment and Research(51), Cancer, Lipids, and Metabolism(37), Estrogen and related hormone effects(29), Cytokine Signaling Pathways and Interactions(28)

Publications374 total

Supplementary Table S2 from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control
2024Open Access
Data from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control
2024Open Access
Supplementary Table S1 from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control
2024Open Access
Supplementary Figure 1-9 from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control
2024Open Access
Supplementary Figure Legends from Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control
2024Open Access
Discovery, preclinical validation and early human imaging with [11C]AZ14193391 – the first blood-brain barrier permeable and subtype selective PARP1 PET radioligand
Nuclear Medicine and Biology·2023· 4 cited
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
European Journal of Cancer·2023· 14 citedOpen Access
43P AKT and estrogen receptor (ER) inhibition potently impairs endocrine resistance (EndoR) in breast cancer (BC)
ESMO Open·2023Open Access
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells
Cell Reports·2023· 5 citedOpen Access
Abstract 6330: Countering antidrug antibodies to programmed cell death-1 blockade in mouse <i>Pten</i>-null prostate cancer
Cancer Research·2023
supplementary Table 4 from Identification of Pharmacodynamic Transcript Biomarkers in Response to &lt;i&gt;FGFR&lt;/i&gt; Inhibition by AZD4547
2023Open Access
Supplementary Figure 5 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
2023Open Access
supplementary figure and table legend from Identification of Pharmacodynamic Transcript Biomarkers in Response to &lt;i&gt;FGFR&lt;/i&gt; Inhibition by AZD4547
2023Open Access
supplementary Table 2 from Identification of Pharmacodynamic Transcript Biomarkers in Response to &lt;i&gt;FGFR&lt;/i&gt; Inhibition by AZD4547
2023Open Access
S3. Temporal effect of the combination of AZD5363 with endocrine therapy on PI3K/mTOR/AKT, ER and cell cycle signalling. from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) &lt;i&gt;In Vivo&lt;/i&gt;
2023Open Access
Data from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
2023Open Access
Supplementary Figure 4 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
2023Open Access
Data from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER&lt;sup&gt;+&lt;/sup&gt; Breast Cancer When Administered Using Intermittent or Continuous Schedules
2023Open Access
S1. Antiproliferative effect of escalating doses of AZD5363 in endocrine sensitive and resistant cell lines {plus minus} estrogen or androstenedione. from AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) &lt;i&gt;In Vivo&lt;/i&gt;
2023Open Access
Data from Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
2023Open Access
page 1 of 19Next →

Frequent Co-authors

Claire Crafter(9), Martin Pass(7), Sabina Cosulich(6), Armelle Logié(5), Paul D. Smith(5), Phillippa Dudley(4), Sylvie M. Guichard(4), Neil H. James(4), Emma Dean(4), Elaine Cadogan(4), Robert W. Wilkinson(4), Philip S. Rudland(4), Christine M. Chresta(3), Rebecca Ellston(3), Jingchuan Zhang(3), James Yates(3), Donald Ogilvie(3), Antonio Ramos‐Montoya(3), Mercedes Vázquez–Chantada(3), David T. Beattie(3)